Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.

Hanrahan JP, Wakefield JD, Wilson PJ, Mihova M, Chickering JG, Ruff D, Hall M, Milne GT, Currie MG, Profy AT.

Clin Pharmacol Drug Dev. 2019 Jul;8(5):564-575. doi: 10.1002/cpdd.627. Epub 2018 Nov 13.

PMID:
30422390
2.

Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.

Buys ES, Zimmer DP, Chickering J, Graul R, Chien YT, Profy A, Hadcock JR, Masferrer JL, Milne GT.

Nitric Oxide. 2018 Aug 1;78:72-80. doi: 10.1016/j.niox.2018.05.009. Epub 2018 May 31. Review.

3.

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.

Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, Tang K, Im GJ, Sheppeck J 2nd, Moore JD, Sykes K, Wakefield J, Sarno R, Banijamali AR, Profy AT, Milne GT, Currie MG, Masferrer JL.

J Pharmacol Exp Ther. 2018 Jun;365(3):664-675. doi: 10.1124/jpet.117.247429. Epub 2018 Apr 11.

PMID:
29643251
4.

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.

Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, M√Ęsse B, Hillier SL, Soto-Torres L; HIV Prevention Trials Network (HPTN) 035 Study Team.

AIDS. 2011 Apr 24;25(7):957-66. doi: 10.1097/QAD.0b013e32834541d9.

5.

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J.

Lancet. 2010 Oct 16;376(9749):1329-37. doi: 10.1016/S0140-6736(10)61086-0. Epub 2010 Sep 17.

6.

A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.

Kamali A, Byomire H, Muwonge C, Bakobaki J, Rutterford C, Okong P, Profy A, Byaruhanga R, Namukwaya S, McCormack S, Grosskurth H, Nunn AJ, Lacey CJ.

Sex Transm Infect. 2010 Jun;86(3):222-6. doi: 10.1136/sti.2009.038372. Epub 2010 May 5.

PMID:
20444744
7.

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, Madan RP, Cohen HW, Petrie J, Ford T, Soto-Torres L, Profy AT, Herold BC.

PLoS One. 2010 Jan 22;5(1):e8781. doi: 10.1371/journal.pone.0008781.

8.

The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.

Huskens D, Vermeire K, Profy AT, Schols D.

Antiviral Res. 2009 Oct;84(1):38-47. doi: 10.1016/j.antiviral.2009.07.013. Epub 2009 Aug 5.

PMID:
19664662
9.

The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes.

Sachdev DD, Zerhouni-Layachi B, Ortigoza M, Profy AT, Tuen M, Hioe CE, Klotman ME.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):125-9. doi: 10.1097/QAI.0b013e31819f9e31.

10.

Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer.

Teleshova N, Chang T, Profy A, Klotman ME.

Antimicrob Agents Chemother. 2008 May;52(5):1751-8. doi: 10.1128/AAC.00707-07. Epub 2008 Mar 10.

11.

Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides.

Lackman-Smith C, Osterling C, Luckenbaugh K, Mankowski M, Snyder B, Lewis G, Paull J, Profy A, Ptak RG, Buckheit RW Jr, Watson KM, Cummins JE Jr, Sanders-Beer BE.

Antimicrob Agents Chemother. 2008 May;52(5):1768-81. doi: 10.1128/AAC.01328-07. Epub 2008 Mar 3.

12.

PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.

Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, Wallenstein S, Cole AL, Cole AM, Profy AT, Wira CR, Hogarty K, Herold BC.

AIDS. 2007 Feb 19;21(4):467-76.

PMID:
17301565
13.

ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations.

Tuyama AC, Cheshenko N, Carlucci MJ, Li JH, Goldberg CL, Waller DP, Anderson RA, Profy AT, Klotman ME, Keller MJ, Herold BC.

J Infect Dis. 2006 Sep 15;194(6):795-803. Epub 2006 Aug 16.

PMID:
16941346
14.
15.

Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study.

Lacey CJ, Wright A, Weber JN, Profy AT.

AIDS. 2006 Apr 24;20(7):1027-30.

PMID:
16603855
16.

Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned.

Joshi S, Dutta S, Bell B, Profy A, Kuruc J, Fang G, Cianciola M, Maslankowski L, Soto-Torres L, Panchanadikar A, Mehendale S, Reynolds SJ.

AIDS Res Hum Retroviruses. 2006 Mar;22(3):294-6. No abstract available.

PMID:
16545017
17.

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC.

J Infect Dis. 2006 Jan 1;193(1):27-35. Epub 2005 Nov 17.

PMID:
16323128
18.

Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.

Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, Jarvis GA, Keller MJ, Hogarty K, Waller DP, Profy AT, Herold BC, Klotman ME.

Antimicrob Agents Chemother. 2005 Sep;49(9):3607-15.

19.

Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.

Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, Li JH, Hogarty K, Anderson RA, Waller DP, Zaneveld LJ, Profy AT, Klotman ME, Herold BC.

Antimicrob Agents Chemother. 2004 Jun;48(6):2025-36.

20.

Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.

Stanfield RL, Ghiara JB, Ollmann Saphire E, Profy AT, Wilson IA.

Virology. 2003 Oct 10;315(1):159-73.

21.

The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.

Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, Morar N, Maslankowski L, Profy AT, Kelly C, Abdool Karim SS, Mayer KH.

J Womens Health (Larchmt). 2003 Sep;12(7):655-66.

PMID:
14583106
22.

Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.

Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter III AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, Van Damme L, Celum CL.

J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):476-83. Erratum in: J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):118.

PMID:
12869836
23.

Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.

Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z; HIV Prevention Trials Network (HPTN) 020 Protocol Team.

AIDS. 2003 Feb 14;17(3):321-9.

PMID:
12556685
24.

A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.

Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, McKinlay M, Van Dyck E, Weber J, Profy A, Laga M, Kitchen V.

Sex Transm Infect. 2000 Apr;76(2):126-30.

25.

Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120.

Ferrer M, Sullivan BJ, Godbout KL, Burke E, Stump HS, Godoy J, Golden A, Profy AT, van Schravendijk MR.

J Pept Res. 1999 Jul;54(1):32-42.

PMID:
10448968
26.

Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.

Stanfield R, Cabezas E, Satterthwait A, Stura E, Profy A, Wilson I.

Structure. 1999 Feb 15;7(2):131-42.

27.

The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model.

Bourne N, Bernstein DI, Ireland J, Sonderfan AJ, Profy AT, Stanberry LR.

J Infect Dis. 1999 Jul;180(1):203-5.

PMID:
10353881
28.

Conformational integrity and ligand binding properties of a single chain T-cell receptor expressed in Escherichia coli.

Khandekar SS, Bettencourt BM, Wyss DF, Naylor JW, Brauer PP, Huestis K, Dwyer DS, Profy AT, Osburne MS, Banerji J, Jones B.

J Biol Chem. 1997 Dec 19;272(51):32190-7.

29.

Affinity and kinetics of the interactions between an alphabeta T-cell receptor and its superantigen and class II-MHC/peptide ligands.

Khandekar SS, Brauer PP, Naylor JW, Chang HC, Kern P, Newcomb JR, Leclair KP, Stump HS, Bettencourt BM, Kawasaki E, Banerji J, Profy AT, Jones B.

Mol Immunol. 1997 Apr;34(6):493-503.

PMID:
9307065
30.

Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.

Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, Willis KJ, Osburne MS, Profy AT, Jenson JC, Hirsch MS.

Antimicrob Agents Chemother. 1996 Jan;40(1):234-6.

31.

Crystal structure of the principal neutralization site of HIV-1.

Ghiara JB, Stura EA, Stanfield RL, Profy AT, Wilson IA.

Science. 1994 Apr 1;264(5155):82-5.

PMID:
7511253
32.

Major antigen-induced domain rearrangements in an antibody.

Stanfield RL, Takimoto-Kamimura M, Rini JM, Profy AT, Wilson IA.

Structure. 1993 Oct 15;1(2):83-93.

PMID:
8069628
33.

Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen.

Rini JM, Stanfield RL, Stura EA, Salinas PA, Profy AT, Wilson IA.

Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6325-9.

34.

Crystallization, sequence, and preliminary crystallographic data for an antipeptide Fab 50.1 and peptide complexes with the principal neutralizing determinant of HIV-1 gp120.

Stura EA, Stanfield RL, Fieser GG, Silver S, Roguska M, Hincapie LM, Simmerman HK, Profy AT, Wilson IA.

Proteins. 1992 Dec;14(4):499-508.

PMID:
1438187
35.

A chemically defined synthetic vaccine model for HIV-1.

Nardelli B, Lu YA, Shiu DR, Delpierre-Defoort C, Profy AT, Tam JP.

J Immunol. 1992 Feb 1;148(3):914-20.

PMID:
1370524
36.
37.

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications.

LaRosa GJ, Weinhold K, Profy AT, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Bolognesi DP, Matthews TJ, Emini EA, et al.

Science. 1991 Sep 6;253(5024):1146. No abstract available.

PMID:
1887238
38.

Immunoassay to measure staphylococcal protein A in the presence of murine immunoglobulins.

Knicker SM, Profy AT.

J Immunol Methods. 1991 Aug 28;142(1):53-9.

PMID:
1919021
39.

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: corrections and clarifications.

LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, et al.

Science. 1991 Feb 15;251(4995):811. No abstract available.

PMID:
1990444
40.

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Javaherian K, Langlois AJ, LaRosa GJ, Profy AT, Bolognesi DP, Herlihy WC, Putney SD, Matthews TJ.

Science. 1990 Dec 14;250(4987):1590-3. Erratum in: Science 1991 Jan 4;251(4989):13.

PMID:
1703322
41.

Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.

Scott CF Jr, Silver S, Profy AT, Putney SD, Langlois A, Weinhold K, Robinson JE.

Proc Natl Acad Sci U S A. 1990 Nov;87(21):8597-601.

42.

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, et al.

Science. 1990 Aug 24;249(4971):932-5. Erratum in: Science. 1991 Feb 15;251(4995):811.

PMID:
2392685
43.

Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.

Profy AT, Salinas PA, Eckler LI, Dunlop NM, Nara PL, Putney SD.

J Immunol. 1990 Jun 15;144(12):4641-7.

PMID:
1693639
44.

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, et al.

Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72.

45.

Complementary use of chemical modification and site-directed mutagenesis to probe structure-activity relationships in enzymes.

Profy AT, Schimmel P.

Prog Nucleic Acid Res Mol Biol. 1988;35:1-26. Review. No abstract available.

PMID:
3065821
46.
47.

Stereoselective aminoacylation of polyribonucleotides.

Profy AT, Usher DA.

J Am Chem Soc. 1984;106:5030-1. No abstract available.

PMID:
11541982
48.

Nucleic acids, proteins, and chirality.

Usher DA, Profy AT, Walstrum SA, Needels MC, Bulack SC, Lo KM.

Orig Life. 1984;14(1-4):621-8. No abstract available.

PMID:
6462697

Supplemental Content

Support Center